Yinying Wu

813 total citations
46 papers, 538 citations indexed

About

Yinying Wu is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Yinying Wu has authored 46 papers receiving a total of 538 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 17 papers in Molecular Biology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Yinying Wu's work include Neuroendocrine Tumor Research Advances (7 papers), Pancreatic and Hepatic Oncology Research (6 papers) and Angiogenesis and VEGF in Cancer (6 papers). Yinying Wu is often cited by papers focused on Neuroendocrine Tumor Research Advances (7 papers), Pancreatic and Hepatic Oncology Research (6 papers) and Angiogenesis and VEGF in Cancer (6 papers). Yinying Wu collaborates with scholars based in China, United States and Hong Kong. Yinying Wu's co-authors include Enxiao Li, Qianqian Geng, Yangwei Fan, Ke Ma, Yuan Hu, Juan Ren, Danfeng Dong, Jiangzhou Zhang, Shuheng Bai and Xiaozhi Zhang and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Scientific Reports.

In The Last Decade

Yinying Wu

42 papers receiving 531 citations

Peers

Yinying Wu
Anand Rajan United States
Jinfei Xu United States
Yinying Wu
Citations per year, relative to Yinying Wu Yinying Wu (= 1×) peers Taiji Hamada

Countries citing papers authored by Yinying Wu

Since Specialization
Citations

This map shows the geographic impact of Yinying Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yinying Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yinying Wu more than expected).

Fields of papers citing papers by Yinying Wu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yinying Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yinying Wu. The network helps show where Yinying Wu may publish in the future.

Co-authorship network of co-authors of Yinying Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Yinying Wu. A scholar is included among the top collaborators of Yinying Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yinying Wu. Yinying Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Jian, Yun Liang, Long Jiang, et al.. (2025). Efficacy and safety of surufatinib in unresectable or metastatic grade 3 pancreatic neuroendocrine tumors (NET G3): Real-world analysis.. Journal of Clinical Oncology. 43(4_suppl). 657–657.
2.
Wu, Yinying, Yangwei Fan, Yu Shi, et al.. (2025). A multi-omics prognostic model of cuproptosis affects the prognosis of stomach adenocarcinoma. Clinical Epigenetics. 17(1). 99–99. 1 indexed citations
3.
4.
Wu, Yinying, et al.. (2024). Tislelizumab with anlotinib and chemotherapy for second-line treatment of pancreatic ductal adenocarcinoma: A pilot study early result.. Journal of Clinical Oncology. 42(16_suppl). e16316–e16316. 1 indexed citations
6.
Wang, Xi, Chengsheng Zhang, Yuan Hu, et al.. (2022). Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma. World Journal of Gastrointestinal Oncology. 14(7). 1252–1264. 31 indexed citations
7.
Jin, Jiabin, Yina Jiang, Yinying Wu, et al.. (2022). Development and external validation of a dynamic nomogram to predict the survival for adenosquamous carcinoma of the pancreas. Frontiers in Oncology. 12. 927107–927107. 11 indexed citations
8.
Li, Wei, Xue Yang, Yuan Deng, et al.. (2022). Necrolytic migratory erythema is an important visual cutaneous clue of glucagonoma. Scientific Reports. 12(1). 9053–9053. 4 indexed citations
9.
Shi, Yu, Liankang Sun, Rui Zhang, et al.. (2021). Thrombospondin 4/integrin α2/HSF1 axis promotes proliferation and cancer stem-like traits of gallbladder cancer by enhancing reciprocal crosstalk between cancer-associated fibroblasts and tumor cells. Journal of Experimental & Clinical Cancer Research. 40(1). 14–14. 42 indexed citations
10.
Wu, Yinying, et al.. (2020). Efficacy and safety of regorafenib as beyond second-line therapy in patients with metastatic colorectal cancer: an adjusted indirect meta-analysis and systematic review. Therapeutic Advances in Medical Oncology. 12. 3863555972–3863555972. 7 indexed citations
11.
Wu, Yinying, Shuheng Bai, Yanli Yan, et al.. (2020). Long non‐coding RNA SNGH7 Is activated by SP1 and exerts oncogenic properties by interacting with EZH2 in ovarian cancer. Journal of Cellular and Molecular Medicine. 24(13). 7479–7489. 25 indexed citations
12.
Bai, Shuheng, Yinying Wu, Yanli Yan, et al.. (2020). The effect of CCL5 on the immune cells infiltration and the prognosis of patients with kidney renal clear cell carcinoma. International Journal of Medical Sciences. 17(18). 2917–2925. 10 indexed citations
13.
Bai, Shuheng, Yinying Wu, Yanli Yan, et al.. (2020). Construct a circRNA/miRNA/mRNA regulatory network to explore potential pathogenesis and therapy options of clear cell renal cell carcinoma. Scientific Reports. 10(1). 13659–13659. 64 indexed citations
14.
Tan, Li Tee, Yinying Wu, Xiaowei Ma, et al.. (2019). A Comprehensive Meta-Analysis of Association between EGFR Mutation Status and Brain Metastases in NSCLC. Pathology & Oncology Research. 25(2). 791–799. 13 indexed citations
15.
Yang, Jiao, Shuting Li, Meng Lv, et al.. (2017). Risk of subsequent primary malignancies among patients with prior colorectal cancer: a population-based cohort study. OncoTargets and Therapy. Volume 10. 1535–1548. 13 indexed citations
16.
Ma, Ke, et al.. (2017). PD-L1 and PD-1 expression correlate with prognosis in extrahepatic cholangiocarcinoma. Oncology Letters. 14(1). 250–256. 50 indexed citations
17.
Yang, Jiao, Shuting Li, Biyuan Wang, et al.. (2016). Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer. Tumor Biology. 37(9). 11645–11655. 21 indexed citations
18.
Fan, Yangwei, Ke Ma, Chuying Wang, et al.. (2016). Prognostic value of PD-L1 and PD-1 expression in pulmonary neuroendocrine tumors. OncoTargets and Therapy. Volume 9. 6075–6082. 45 indexed citations
19.
Ma, Ke, Chuying Wang, Qianqian Geng, et al.. (2016). Recombinant adeno-associated virus-delivered anginex inhibits angiogenesis and growth of HUVECs by regulating the Akt, JNK and NF-κB signaling pathways. Oncology Reports. 35(6). 3505–3513. 3 indexed citations
20.
Wu, Yinying. (2011). A Survey that the Cancer Patients Flow to and the Feasibility of Establishment Tertiary Prevention and Control Network for Cancer. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026